找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Hot Carriers in Semiconductors; Karl Hess,Jean-Pierre Leburton,Umberto Ravaioli Book 1996 Plenum Press, New York 1996 Exciton.MOSFET.Semic

[復(fù)制鏈接]
樓主: Extraneous
51#
發(fā)表于 2025-3-30 09:29:33 | 只看該作者
52#
發(fā)表于 2025-3-30 14:00:30 | 只看該作者
53#
發(fā)表于 2025-3-30 20:14:15 | 只看該作者
F. Yang,G. R. Hayes,R. T. Phillips,K. P. O’Donnell regimens including high dose cytarabine are appropriate for patients with myeloid EML. Presence of EML should not be used alone to determine need for stem cell transplant (SCT). Risk-adapted treatment should utilize genetic markers and disease response that includes assessment of remission in EML s
54#
發(fā)表于 2025-3-30 22:46:40 | 只看該作者
R. Hellmann,A. Euteneur,S. G. Hense,J. Feldmann,P. Thomas,E. O. G?bel,A. Waag,G. Landwehr9–1886, 2020). This correlates with approximately one in every three pediatric AML patients dying, and the price for cure among survivors includes a significant increase in long-term chronic health conditions (Bhatt et al., Leukemia 35(8):2258–2273, 2021). Further improvement is badly needed. Within
55#
發(fā)表于 2025-3-31 00:53:36 | 只看該作者
Yu. L. Ivanov,G. V. Churakov,V. M. Ustinov,A. E. Zhukov regimens including high dose cytarabine are appropriate for patients with myeloid EML. Presence of EML should not be used alone to determine need for stem cell transplant (SCT). Risk-adapted treatment should utilize genetic markers and disease response that includes assessment of remission in EML s
56#
發(fā)表于 2025-3-31 05:59:35 | 只看該作者
57#
發(fā)表于 2025-3-31 11:09:53 | 只看該作者
58#
發(fā)表于 2025-3-31 15:22:00 | 只看該作者
59#
發(fā)表于 2025-3-31 18:10:49 | 只看該作者
60#
發(fā)表于 2025-4-1 01:16:15 | 只看該作者
Jürgen Schilp,Tilmann Kuhnf existing legislation is required in order to make the EU liability framework fit for the current and forthcoming technological and commercial developments. In addition, this chapter provides an extensive review of the Commission’s 2020 Report on the safety and liability implications of AI, IoT and
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 03:38
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
肇州县| 海原县| 长治市| 泊头市| 临泉县| 长子县| 台北市| 天镇县| 宁河县| 定日县| 铁岭市| 天峻县| 东安县| 普安县| 大田县| 财经| 泽普县| 高雄县| 内江市| 浏阳市| 全州县| 黑水县| 镇宁| 习水县| 思南县| 汉中市| 丹巴县| 大悟县| 开远市| 白河县| 韩城市| 沂水县| 靖宇县| 新乡市| 长汀县| 毕节市| 菏泽市| 灌阳县| 河东区| 伊金霍洛旗| 龙胜|